Return to content in this issue

 

Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia

Shimizu Y1, Kurosawa M2, Sutoh Y3, Sutoh E2,3

1Division of Respiratory Medicine, Kaminakai Family Clinic, Takasaki, Gunma, Japan
2Department of Allergy and Respiratory Medicine, Sutoh Hospital, Annaka, Gunma, Japan
3Department of Surgery, Sutoh Hospital, Annaka, Gunma, Japan

J Investig Allergol Clin Immunol 2020; Vol 30(2) : 154-155
doi: 10.18176/jiaci.0468

Key words: Benralizumab, Chronic eosinophilic pneumonia, Antiinterleukin 5 antibody, Mepolizumab